These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 15282667

  • 1. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
    Santamaría A, Borrell M, Oliver A, Ortín R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J.
    Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 3. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
    Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M.
    Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 5. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
    Gumus K, Kadayifcilar S, Eldem B, Ozcebe O.
    Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
    [Abstract] [Full Text] [Related]

  • 6. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2006 Jul; 38(1):105-7. PubMed ID: 16504676
    [Abstract] [Full Text] [Related]

  • 8. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
    Alacacioğlu I, Ozcan MA, Alacacioğlu A, Polat M, Yüksel F, Demirkan F, Pişkin O, Ozgenç Y, Ozsan HG, Undar B.
    Thromb Res; 2004 Jul; 114(3):155-9. PubMed ID: 15342211
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
    Mokhtar GM, Matter RM, Shawki H, Abdel Aziz MM.
    Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
    [Abstract] [Full Text] [Related]

  • 10. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A.
    Przegl Lek; 2006 Aug; 63(12):1281-5. PubMed ID: 17642140
    [Abstract] [Full Text] [Related]

  • 11. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
    Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, Blombäck M, Antovic J.
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):365-70. PubMed ID: 17473579
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Cağlayan O, Saygili F, Yilmaz C.
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
    [Abstract] [Full Text] [Related]

  • 13. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK, Stewart RJ, Schneider MM, Nesheim ME.
    Anal Biochem; 2004 Jul 15; 330(2):332-41. PubMed ID: 15203340
    [Abstract] [Full Text] [Related]

  • 14. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
    Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J.
    Haematologica; 2004 Jul 15; 89(7):880-1. PubMed ID: 15257950
    [Abstract] [Full Text] [Related]

  • 15. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Jul 15; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 16. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
    Folkeringa N, Coppens M, Veeger NJ, Bom VJ, Middeldorp S, Hamulyak K, Prins MH, Büller HR, van der Meer J.
    Thromb Haemost; 2008 Jul 15; 100(1):38-44. PubMed ID: 18612536
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
    Lisowski P, Małyszko J, Hirnle T, Lisowska A, Jackowski R, Małyszko JS, Buzun L, Myśliwiec M.
    Rocz Akad Med Bialymst; 2005 Jul 15; 50():166-72. PubMed ID: 16358959
    [Abstract] [Full Text] [Related]

  • 18. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
    Guven GS, Kiliçaslan A, Oz SG, Haznedaroglu IC, Kirazli S, Aslan D, Sözen T.
    Clin Appl Thromb Hemost; 2006 Jul 15; 12(3):364-8. PubMed ID: 16959692
    [Abstract] [Full Text] [Related]

  • 19. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M.
    Am J Gastroenterol; 2004 Oct 15; 99(10):1966-70. PubMed ID: 15447757
    [Abstract] [Full Text] [Related]

  • 20. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct 15; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.